Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -34.75% is 29% below its 5-year average of -26.84%, near the low end of its 5-year range (-34.75%–-21.71%).
46.44% below its 12-month average of -23.73%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.96%.
RETURN ON ASSETS (ROA)
-34.75%
RETURN ON ASSETS (ROA) AVG TTM
-23.73%
RETURN ON ASSETS (ROA) AVG 3Y
-25.63%
RETURN ON ASSETS (ROA) AVG 5Y
-26.84%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-46.44%
CURRENT VS 3Y AVG
-35.56%
CURRENT VS 5Y AVG
-29.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-7.79%
vs the sector median at left
Nkarta, Inc.
Market Cap
$165.60M
Return on Assets (ROA)
-34.75%
TTM Avg
-23.73%
3Y Avg
-25.63%
5Y Avg
-26.84%
Market Cap
$165.51M
Return on Assets (ROA)
2.80%
TTM Avg
-4.42%
3Y Avg
-6.73%
5Y Avg
-5.05%
Market Cap
$168.61M
Return on Assets (ROA)
-534.43%
TTM Avg
-94.69%
3Y Avg
-82.47%
5Y Avg
-71.30%
Market Cap
$162.75M
Return on Assets (ROA)
-38.52%
TTM Avg
-17.54%
3Y Avg
-16.16%
5Y Avg
-14.54%
Market Cap
$169.10M
Return on Assets (ROA)
-28.07%
TTM Avg
-34.40%
3Y Avg
-29.52%
5Y Avg
-36.05%
Market Cap
$169.44M
Return on Assets (ROA)
-22.20%
TTM Avg
3.18%
3Y Avg
2.72%
5Y Avg
6.35%
Market Cap
$160.98M
Return on Assets (ROA)
-414.72%
TTM Avg
-147.82%
3Y Avg
-101.66%
5Y Avg
-78.00%
Market Cap
$170.22M
Return on Assets (ROA)
-6.21%
TTM Avg
-15.18%
3Y Avg
-15.88%
5Y Avg
-16.43%
Market Cap
$170.58M
Return on Assets (ROA)
-41.88%
TTM Avg
-12.18%
3Y Avg
-27.40%
5Y Avg
-32.78%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nkarta, Inc. (NKTX) | $165.60M | -34.75% | -23.73% | -25.63% | -26.84% |
| OptimizeRx Corp. (OPRX)vs › | $165.51M | 2.80% | -4.42% | -6.73% | -5.05% |
| Cue Biopharma, Inc. (CUE)vs › | $168.61M | -534.43% | -94.69% | -82.47% | -71.30% |
| Quanterix Corporation (QTRX)vs › | $162.75M | -38.52% | -17.54% | -16.16% | -14.54% |
| MediWound Ltd. (MDWD)vs › | $169.10M | -28.07% | -34.40% | -29.52% | -36.05% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.44M | -22.20% | 3.18% | 2.72% | 6.35% |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.98M | -414.72% | -147.82% | -101.66% | -78.00% |
| Journey Medical Corporation (DERM)vs › | $170.22M | -6.21% | -15.18% | -15.88% | -16.43% |
| Precision BioSciences, Inc. (DTIL)vs › | $170.58M | -41.88% | -12.18% | -27.40% | -32.78% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.91M | -68.50% | -29.78% | -39.51% | -30.76% |
ROA
-34.8%
ROE
-47.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -25.75% |
| 2024-12-31 | -21.71% |
| 2023-12-31 | -31.01% |
| 2022-12-31 | -24.07% |
| 2021-12-31 | -31.43% |
| 2020-12-31 | -27.06% |
| 2019-12-31 | -43.53% |
| 2018-12-31 | -2.86% |
